JP2023524997A5 - - Google Patents
Info
- Publication number
- JP2023524997A5 JP2023524997A5 JP2022567343A JP2022567343A JP2023524997A5 JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5 JP 2022567343 A JP2022567343 A JP 2022567343A JP 2022567343 A JP2022567343 A JP 2022567343A JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020806P | 2020-05-06 | 2020-05-06 | |
| US63/020,806 | 2020-05-06 | ||
| PCT/US2021/030773 WO2021226163A2 (en) | 2020-05-06 | 2021-05-05 | Antibodies targeting clec12a and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524997A JP2023524997A (ja) | 2023-06-14 |
| JP2023524997A5 true JP2023524997A5 (enExample) | 2024-05-16 |
Family
ID=78468386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567343A Pending JP2023524997A (ja) | 2020-05-06 | 2021-05-05 | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220084A1 (enExample) |
| EP (1) | EP4146704A4 (enExample) |
| JP (1) | JP2023524997A (enExample) |
| KR (1) | KR20230008157A (enExample) |
| CN (1) | CN115697402A (enExample) |
| AU (1) | AU2021267023A1 (enExample) |
| BR (1) | BR112022022418A2 (enExample) |
| CA (1) | CA3177818A1 (enExample) |
| IL (1) | IL297950A (enExample) |
| MX (1) | MX2022013882A (enExample) |
| WO (1) | WO2021226163A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| GB202214132D0 (en) * | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710572A2 (pt) * | 2006-01-24 | 2013-01-08 | Domantis Limited | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| TW201718647A (zh) * | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| KR102644544B1 (ko) * | 2016-09-21 | 2024-03-11 | 넥스트큐어 인코포레이티드 | Siglec-15를 위한 항체 및 이의 사용 방법 |
| MX2020002880A (es) * | 2017-09-14 | 2020-10-01 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). |
| WO2020052543A1 (en) * | 2018-09-10 | 2020-03-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cd33 and constructs thereof |
-
2021
- 2021-05-05 WO PCT/US2021/030773 patent/WO2021226163A2/en not_active Ceased
- 2021-05-05 JP JP2022567343A patent/JP2023524997A/ja active Pending
- 2021-05-05 MX MX2022013882A patent/MX2022013882A/es unknown
- 2021-05-05 CN CN202180033626.0A patent/CN115697402A/zh active Pending
- 2021-05-05 BR BR112022022418A patent/BR112022022418A2/pt not_active IP Right Cessation
- 2021-05-05 US US17/923,411 patent/US20230220084A1/en active Pending
- 2021-05-05 EP EP21799694.1A patent/EP4146704A4/en active Pending
- 2021-05-05 IL IL297950A patent/IL297950A/en unknown
- 2021-05-05 AU AU2021267023A patent/AU2021267023A1/en not_active Abandoned
- 2021-05-05 KR KR1020227042237A patent/KR20230008157A/ko active Pending
- 2021-05-05 CA CA3177818A patent/CA3177818A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551757A5 (enExample) | ||
| TWI899054B (zh) | 治療癌症及增強ｔ細胞重定向治療劑之功效的方法（一） | |
| JP2024537772A5 (enExample) | ||
| JP2021526844A5 (enExample) | ||
| IL311600A (en) | Antibodies targeting BAFF-R and their use | |
| IL317912A (en) | A combined chimeric antigen receptor targeting CD19 and CD20 and its applications | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2023546766A5 (enExample) | ||
| CA3091424A1 (en) | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use | |
| CA3091764A1 (en) | Antibody variable domains targeting cd33, and use thereof | |
| EA037065B1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
| WO2017142928A1 (en) | Ror1-binding molecules, and methods of use thereof | |
| TW201702265A (zh) | 結合lag-3的分子和其使用方法 | |
| JP2022520455A5 (enExample) | ||
| CA2962603A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof | |
| WO2016122701A1 (en) | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof | |
| JP2023546764A5 (enExample) | ||
| CN115348972A (zh) | 靶向flt3的抗体及其用途 | |
| JP2024534847A5 (enExample) | ||
| JP2023525778A5 (enExample) | ||
| EP3558368A1 (en) | Adam9-binding molecules, and methods of use thereof | |
| JP2023553390A5 (enExample) | ||
| AU2017278329A1 (en) | Methods for the use of CD32B x CD79B-binding molecules in the treatment of inflammatory diseases and disorders | |
| JP2022508529A (ja) | 二重標的抗原結合分子 |